Joel Latham

Recent appearances

• 

  Building Incannex: A NASDAQ Biotech Taking On Sleep Apnea | Joel Latham | LOB Ep.14

  September 09, 2026 · 📺 Biotecnika

  In this episode of Legends of Biotech, Shekhar Suman sits down with Joel Latham, President & CEO of Incannex Healthcare, to discuss biotech leadership, drug development, clinical trials, and the future of therapeutics. Joel shares insights on obstructive sleep apnea, generalized anxiety disorder, psychedelic-assisted therapy, FDA regulations, AI in drug development, and leading a biotech company across global markets. He also shares valuable advice for young scientists and aspiring biotech leaders on building a successful career through passion, persistence, and innovation. 🎙️ Guest: Joel L…

  Watch on YouTube ↗

• 

  Joel Latham: Building Incannex & Betting on the Future of Biotech

  July 27, 2026 · 📺 LegendsNLeaders

  Joel Latham, CEO of Incannex, joins LegendsNLeaders to share his journey building and leading a biotechnology company focused on developing new therapies for major unmet medical needs. Joel takes us through his path to Incannex, the challenges of building a biotech company, and what it takes to move new treatments from an idea through development and toward commercialization. In this episode, Joel discusses the realities of the biotech industry, raising capital, navigating clinical development and regulation, building a public company, and making long-term bets in an industry where breakthro…

  Watch on YouTube ↗

• 

  Joel Latham - CEO, Incannex - Combination Therapies For Challenging Chronic Conditions

  January 22, 2026 · 📺 Progress, Potential, and Possibilities

  Joel Latham is the Chief Executive Officer, President, and Director of Incannex Healthcare Inc. ( https://incannex.com/ ) a science-led combination medicines company leading the way in developing cannabinoid-based medicines and psychedelic-based regimens for people living with challenging chronic conditions. Incannex Healthcare’s science-driven programs are exploring the therapeutic potential of oral synthetic cannabinoid and psilocybin drug candidates in sleep apnea, anxiety, and inflammatory diseases. Joel brings more than 20 years of senior management and operations experience in both pu…

  Watch on YouTube ↗

• 

  Incannex Healthcare - $IXHL - Ep:040 - Nano Cap Podcast

  January 19, 2026 · 📺 Nano Cap Podcast

  In this Episode, Joel Latham, CEO of Incannex Healthcare, discusses his career journey, the innovative approaches of Incannex Healthcare in drug development, particularly focusing on combination therapies involving cannabinoids and psychedelics. He highlights the company's unique solutions for obstructive sleep apnea and other chronic conditions, emphasizing the importance of patient-centric approaches and the potential for significant market impact. Latham also shares insights into the future vision of Incannex Healthcare and the expected advancements in their lead assets. INCANNEX WEBSIT…

  Watch on YouTube ↗

• 

  Exploring the Future of Cannabinoid & Psychedelic Therapies with Joel Latham of Incannex Healthcare

  September 30, 2025 · 📺 Xtalks

  In this episode of the Xtalks Life Science Podcast, Senior Life Science Journalist Ayesha Rashid speaks with Joel Latham, CEO, president and director of Incannex Healthcare, to discuss how the company is advancing cannabinoid and psychedelic therapies for chronic conditions like sleep apnea, rheumatoid arthritis and anxiety disorders. Joel has more than 20 years of senior management and operations experience in both public and private sectors. Under Joel’s leadership, Incannex has advanced and prioritized multiple therapeutic candidates into clinical-stage development. Previously, he was the…

  Watch on YouTube ↗

• 

  Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham

  September 21, 2025 · 📺 Life Science Connect

  On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. Joel walks through his funding strategy for the publicly traded company, his desire to lead in a new category of medicine, and what comes next. Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com --- #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - https://podcasts.apple.com…

  Watch on YouTube ↗

• 

  Joel Latham, Incannex Healthcare, on a Promising New Combination Therapy for Obstructive Sleep Apnea

  June 17, 2024 · 📺 DocWire

  Recently, Incannex Healthcare Inc. announced that patient dosing has commenced in their Phase 2/3 RePOSA clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA). OSA is significantly undertreated in that there are no FDA approved prescribed medications and patient compliance to positive air way pressure (PAP) devices is low. Earlier studies demonstrated that IHL-42X reduced the apnea hypopnea index (AHI), the standard measure of OSA, by an average of greater than 50% at the low dose and 25% of those patients had an 80% reduction. DocWire New…

  Watch on YouTube ↗

• 

  Say goodbye to CPAP machines? Incannex CEO talks about potential user-friendly pill form solution

  May 14, 2024 · 📺 Quantum

  Joel Latham, Managing Director and CEO of Incannex Healthcare Inc, shares with Jane King from Nasdaq about: 💊 IHL-42X, a novel cannabinoid combination product for the treatment of Obstructive Sleep Apnoea (OSA) 📊 IHL-42X Phase 2 Trial Results 🏥 Upcoming Phase 2 or Phase 3 Pivotal Study Don't miss this insightful conversation on the future of sleep health! #Incannex #SleepLikeAPro #IHL42X #ObstructiveSleepApnoea Incannex Healthcare Inc. is a client of Quantum Media. Quantum Media has collaborated with Jane King, host of Innovators with Jane King show and reporter at Nasdaq, to interview…

  Watch on YouTube ↗

• 

  Nasdaq Interview | Incannex updates on IHL-675A, HCQ-CBD drug candidate for rheumatoid arthritis

  April 15, 2024 · 📺 Quantum

  Joel Latham, Managing Director and CEO of Incannex Healthcare Inc, shares with Jane King from Nasdaq about: 💊 IHL-675A, a drug candidate combining hydroxychloroquine sulphate (HCQ) and cannabidiol (or, CBD), in patients with rheumatoid arthritis (RA) 🔍 Leveling up existing cannabinoid research 🏥 Clarion Clinics in Australia ➡️ Incannex’s PsiGAD Program 📈 Redomiciliation to the US #Incannex #medicinalcannabinoiddrugs #psychedelicmedicinetherapies Incannex Healthcare Inc. is a client of Quantum Media. Quantum Media has collaborated with Jane King, host of Innovators with Jane King show and re…

  Watch on YouTube ↗

• 

  Innovators with Jane King: Incannex Shares Its 3 Lead Assets and Redomiciliation to US

  December 27, 2023 · 📺 Quantum

  Dive into an exciting conversation with Joel Latham, CEO of Incannex, as he sits down with Jane King from Nasdaq to share the company's three lead assets in the cannabis and psychedelic realms. Discover the strategic move that propelled Incannex forward – the redomiciliation to the US, strategically eliminating barriers for investors seeking unparalleled opportunities. Having previously been listed on the ASX, Joel unveils the strategic advantages of this pivotal shift. As the cannabis and psychedelic sectors are still in their infancy, join us in exploring Incannex's vision for growth and t…

  Watch on YouTube ↗

• 

  Incannex Healthcare: Data opens path to treat anxiety

  May 18, 2023 · 📺 Edison

  In March 2023, Incannex Healthcare released interim trial analysis from the first study of its kind into the safety and efficacy of psilocybin for treating generalized anxiety disorder (GAD). In this video, chief scientific officer Dr Mark Bleackley and CEO Joel Latham discuss the Phase II Psi-GAD1 clinical trial, its results and implications with BBC broadcaster Vivienne Parry. Incannex is an Australian dual-listed biotech company developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. Target indications include GAD, the condition being studied in the tri…

  Watch on YouTube ↗

• 

  Incannex Healthcare: Developing cannabinoid treatment for obstructive sleep apnoea

  December 02, 2022 · 📺 Edison

  Incannex Healthcare (Nasdaq: IXHL, ASX: IHL) is an Australian biotech specialising in the development of treatments for chronic conditions using cannabinoids and psychedelic therapies. Incannex has 28 clinical programmes in progress and holds one of the world’s largest portfolios of patented cannabinoid drug formulations and psychedelic treatment regimes. The company’s most advanced clinical asset, IHL-42X, is being developed for the treatment of obstructive sleep apnoea and will see bioavailability and bioequivalence studies roll out in 2023. Watch Dr Mark Bleackley, Incannex’s chief scie…

  Watch on YouTube ↗